Wealth Growth Daily

Health

Regeneron’s Eylea drug sales sag under tough competition

BY Reuters  • May 4, 2023May 4, 2023
(Reuters) -Regeneron Pharmaceuticals Inc’s first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heats up, sending the company’s sh[...]
Read more
Business Health Updated US

Novo Nordisk cuts some US supply of obesity drug Wegovy to cope with demand

BY Reuters  • May 4, 2023May 4, 2023
By Nikolaj Skydsgaard COPENHAGEN (Reuters) -Danish drug developer Novo Nordisk said it would have to halve the supply of starter doses of its popular Wegovy weight-loss drug in the United States to co[...]
Read more
Business Economy Health Updated

CVS Health to pause M&A and focus on integration

BY Reuters  • May 3, 2023May 3, 2023
By Raghav Mahobe and Leroy Leo (Reuters) – CVS Health Corp said on Wednesday it would pause its recent acquisition spree as it focuses on integrating purchases of healthcare service provider Sig[...]
Read more
Business Health Updated

Analysis-Investors see big Novo Nordisk stock boost if obesity drug shows heart benefit

BY Reuters  • May 3, 2023May 3, 2023
By Maggie Fick LONDON (Reuters) – Positive trial data showing Novo Nordisk’s obesity drug helps save and extend lives, not just lose weight, could propel Europe’s best-performing stock eve[...]
Read more
Business Economy Europe Health US

Vanda Pharmaceuticals sues U.S. government over drug trade secrets

BY Reuters  • May 2, 2023May 2, 2023
By Blake Brittain (Reuters) – Vanda Pharmaceuticals Inc has sued the federal government in Washington, D.C., federal court over accusations that the U.S. Food and Drug Administration passed trad[...]
Read more
Business Health US

Amgen sues Novartis to block generic osteoporosis, bone cancer drugs

BY Reuters  • May 2, 2023May 2, 2023
By Blake Brittain (Reuters) – Amgen Inc sued Novartis AG’s Sandoz in New Jersey federal court Monday, accusing Sandoz’s proposed versions of its multibillion-dollar bone-strengthenin[...]
Read more
Business Europe Health Top News US

Prudential Financial profit misses on lower assets under management

BY Reuters  • May 2, 2023May 2, 2023
(Reuters) -Prudential Financial Inc reported a lower-than-expected quarterly profit on Tuesday, as the life insurer saw a decline in assets under management. The respite in the economy after the marke[...]
Read more
Business Economy Health Updated US

Group of EU states seeks to reduce dependency on China for pharmaceuticals

BY Reuters  • May 2, 2023May 2, 2023
By Julia Payne BRUSSELS (Reuters) – A group of 19 European Union member states are pushing for measures to reduce the bloc’s dependency on Chinese imports of pharmaceutical ingredients, a[...]
Read more
Asia Business Economy Europe Health Politics Top News UK

Perfect storm in Minnesota labor market is worrying harbinger for the Fed

BY Reuters  • May 2, 2023May 2, 2023
By Howard Schneider FARIBAULT, Minnesota (Reuters) – Demand for Daikin Applied Americas Inc’s climate control equipment is soaring, and worker recruitment is in hyperdrive, with hiring tri[...]
Read more
Business Canada Economy Environment Health Top News Updated US
« Previous 1 … 15 16 17 18 19 … 52 Next »
Wealth Growth Daily
PRIVACY POLICY

Copyright © 2026 Wealth Growth Daily. All Rights Reserved.

HIGH RISK WARNING

Trading foreign exchange, stocks, options, or futures on margin carries a high level of risk, and may not be suitable for all investors. Before deciding to trade, you should carefully consider your objectives, financial situation, needs and level of experience. Wealth Growth Daily provides general advice that does not take into account your objectives, financial situation or needs. The content of this website must not be construed as personal advice. The possibility exists that you could sustain a loss in excess of your deposited funds and therefore, you should not speculate with capital that you cannot afford to lose. You should be aware of all the risks associated with trading on margin. You should seek advice from an independent financial advisor. Past performance is not necessarily indicative of future success.

101 Marketside Ave. Suite 404 PMB 318 Ponte Vedra, FL 32081 | (321) 325-1551